2018 First Half Year Financial Results Webcast for Mesoblast

Article Stock Quotes (2)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 7/1/2026

1. NKE
2. TSLA
3. MU
4. SPY
5. BE

6. SPCX
7. STZ
8. META
9. ABVX
10. NVDA

Get Alerts MESO Hot Sheet

Price: $14.09 +4.14%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

NEW YORK and MELBOURNE, Australia, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO) (ASX: MSB) today announced it will report financial results for the first half year ended December 31, 2017 in a webcast beginning at 4:30 pm EST on Tuesday, February 27, 2018; 8:30 am Wednesday, February 28, 2018 AEDT.

The live webcast can be accessed via http://webcasting.brrmedia.com/broadcast/5a6ffa22271b41638bdc2f22

To access the call only, dial 1 855 881 1339 (U.S.), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 882151.

The archived webcast will be available on the Investor page of the Company’s website – www.mesoblast.com

About MesoblastMesoblast Limited (Nasdaq: MESO) (ASX: MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.

For further information, please contact:

Julie MeldrumCorporate Communications Mesoblast LimitedT: +61 3 9639 6036E: [email protected]

Schond GreenwayInvestor RelationsMesoblast LimitedT: +1 212 880 2060 E: [email protected]